Nexentis Technologies (NXTS) said its subsidiary MitoCareX Bio has moved its computational drug discovery platform to Google Cloud, aiming to improve capacity, data governance, and operational flexibility.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
